Personalized immunotherapy after melanoma surgery shows promise in preventing return
NCT ID NCT04013854
First seen Nov 06, 2025 · Last updated May 18, 2026 · Updated 22 times
Summary
This study tests whether giving immunotherapy drugs (nivolumab alone or with ipilimumab) after melanoma surgery can prevent the cancer from coming back. The choice of treatment depends on how the tumor responds to a single dose of nivolumab before surgery. About 67 adults with stage III melanoma that can be removed surgically are participating. The goal is to improve recurrence-free survival while managing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Lancaster General Hospital
Lancaster, Pennsylvania, 17601, United States
Conditions
Explore the condition pages connected to this study.